Description: Lyra Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development and commercialization of novel integrated drug and delivery solutions using XTreo technology platform for the localized treatment of patients with ear, nose, and throat diseases. Its XTreo platform is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. The company's product candidates include LYR-210 and LYR-220, which are bioresorbable polymeric matrices for the treatment of chronic rhinosinusitis. Lyra Therapeutics, Inc. was founded in 2005 and is headquartered in Watertown, Massachusetts.
Home Page: lyratherapeutics.com
LYRA Technical Analysis
480 Arsenal Way
Watertown,
MA
02472
United States
Phone:
617 393 4600
Officers
| Name | Title |
|---|---|
| Dr. Maria Palasis Ph.D. | CEO, Pres & Director |
| Mr. Jason Cavalier | CFO, Treasurer & Sec. |
| Mr. R. Donald Elsey MBA | Advisor |
| Ms. Corinne Noyes | Sr. VP of Commercial Strategy & Market Devel. |
| Dr. Harlan W. Waksal M.D. | Exec. Chairman |
| Dr. Carmichael S. Roberts Jr., Ph.D. | Co-Founder |
| Mr. Ray Knox | VP of Operations |
| Dr. Robert Richard Ph.D. | Sr. VP of Technical Operations |
| Ms. Ellen Cavaleri | Sr. VP of Investor Relations & Communications |
| Ms. Vineeta Belanger Ph.D. | Sr. VP of Clinical Affairs |
Exchange: NASDAQ
Country: US : United States of America
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0.9628 |
| Price-to-Sales TTM: | 53.5353 |
| IPO Date: | 2020-05-01 |
| Fiscal Year End: | December |
| Full Time Employees: | 59 |